Company · CIK 0001672619 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
Enliven Therapeutics, Inc. · ELVN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 SForm 4 → | Sep 21, 5:23 pm EDT | Benjamin HohlCHIEF FINANCIAL OFFICER | 6,018 | $50.35 | $303,003 | 38,000 | −13.7% | 10b5-1 |
| Sep 17, 2026 MForm 4 → | Sep 21, 5:23 pm EDT | Benjamin HohlCHIEF FINANCIAL OFFICER | 3,982 | $14.85 | $59,133 | 44,018 | — | 10b5-1 |
| Sep 17, 2026 SForm 4 → | Sep 21, 5:22 pm EDT | Helen Louise CollinsCHIEF MEDICAL OFFICER | 5,000 | $50.35 | $251,754 | 25,000 | −16.7% | 10b5-1 |
| Sep 17, 2026 MForm 4 → | Sep 21, 5:22 pm EDT | Helen Louise CollinsCHIEF MEDICAL OFFICER | 5,000 | $2.48 | $12,400 | 30,000 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 MForm 4 → | Sep 21, 5:23 pm EDT | Benjamin HohlCHIEF FINANCIAL OFFICER | 3,982 | — | — | 181,018 | — | 10b5-1 |
| Sep 17, 2026 MForm 4 → | Sep 21, 5:22 pm EDT | Helen Louise CollinsCHIEF MEDICAL OFFICER | 5,000 | — | — | 106,268 | — | 10b5-1 |